SODIUM PHENYLACET-SOD BENZOATE (sodium benzoate/sodium phenylacetate)
UREA CYCLE DISORDER AGENTS · HYPERAMMONEMIA ·+6
TRIGEN LABORATO
Drug class
Urea Cycle Disorder Agents
Urea cycle disorder agents are a therapeutic class of metabolic medications primarily functioning as nitrogen-scavenging compounds or synthetic enzyme activators. Read more about Urea Cycle Disorder Agents
25 drugs in this class 22 manufacturers
Drugs in Urea Cycle Disorder Agents
SODIUM PHENYLACET-SOD BENZOATE (sodium benzoate/sodium phenylacetate)
UREA CYCLE DISORDER AGENTS · HYPERAMMONEMIA ·+6
ZYDUS PHARMACEU
CARBAGLU (carglumic acid)
UREA CYCLE DISORDER AGENTS · HYPERAMMONEMIA ASSOCIATED WITH N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY ·+2
ORPHAN EUROPE/R
SODIUM PHENYLBUTYRATE
UREA CYCLE DISORDER AGENTS · CARBAMOYL PHOSPHATE SYNTHETASE DEFICIENCY ·+2
PAR HEALTH USA,
SODIUM PHENYLBUTYRATE
UREA CYCLE DISORDER AGENTS · CARBAMOYL PHOSPHATE SYNTHETASE DEFICIENCY ·+2
PAR HEALTH USA,
AMMONUL (sodium benzoate/sodium phenylacetate)
UREA CYCLE DISORDER AGENTS · HYPERAMMONEMIA ·+6
Bausch Health US
PHEBURANE (sodium phenylbutyrate)
UREA CYCLE DISORDER AGENTS · CARBAMOYL PHOSPHATE SYNTHETASE DEFICIENCY ·+2
MEDUNIK USA
OLPRUVA (sodium phenylbutyrate)
UREA CYCLE DISORDER AGENTS · ARGININOSUCCINATE LYASE DEFICIENCY ·+2
ACER THERAPEUTI
BUPHENYL (sodium phenylbutyrate)
UREA CYCLE DISORDER AGENTS · CARBAMOYL PHOSPHATE SYNTHETASE DEFICIENCY ·+2
HORIZON/AMGEN
Filter & compare in the drug finder →
Opens the drug finder with Urea Cycle Disorder Agents preselected. Add indication or manufacturer filters there.
Urea cycle disorder agents are a therapeutic class of metabolic medications primarily functioning as nitrogen-scavenging compounds or synthetic enzyme activators.
These agents, which include sodium phenylbutyrate, glycerol phenylbutyrate, and carglumic acid, work by providing alternative metabolic pathways for waste nitrogen excretion or by restoring critical enzymatic function to prevent the accumulation of neurotoxic ammonia.
They are clinically indicated for the acute management and long-term maintenance of inherited urea cycle disorders—such as ornithine transcarbamylase, carbamoyl phosphate synthetase, and argininosuccinate synthetase deficiencies—typically serving as adjunctive therapy alongside dietary protein restriction to prevent hyperammonemic crises and permanent neurological damage.
-
fda.gov
Urea cycle disorder agents are a therapeutic class of metabolic medications primarily functioning as nitrogen-scavenging compounds or synthetic enzyme activators These agents, which include sodium phenylbutyrate, glycerol phenylbutyrate, and carglumic acid, work by providing alternative metabolic pathways for waste nitrogen excretion or by restoring critical enzymatic function to prevent the accumulation of neurotoxic ammonia They are clinically indicated for the acute management and long-term m...
-
nih.gov
Urea cycle disorder agents are a therapeutic class of metabolic medications primarily functioning as nitrogen-scavenging compounds or synthetic enzyme activators These agents, which include sodium phenylbutyrate, glycerol phenylbutyrate, and carglumic acid, work by providing alternative metabolic pathways for waste nitrogen excretion or by restoring critical enzymatic function to prevent the accumulation of neurotoxic ammonia
-
nih.gov
Urea cycle disorder agents are a therapeutic class of metabolic medications primarily functioning as nitrogen-scavenging compounds or synthetic enzyme activators
-
wa.gov
These agents, which include sodium phenylbutyrate, glycerol phenylbutyrate, and carglumic acid, work by providing alternative metabolic pathways for waste nitrogen excretion or by restoring critical enzymatic function to prevent the accumulation of neurotoxic ammonia
-
fda.gov
They are clinically indicated for the acute management and long-term maintenance of inherited urea cycle disorders—such as ornithine transcarbamylase, carbamoyl phosphate synthetase, and argininosuccinate synthetase deficiencies—typically serving as adjunctive therapy alongside dietary protein restriction to prevent hyperammonemic crises and permanent neurological damage
-
ravictihcp.com
They are clinically indicated for the acute management and long-term maintenance of inherited urea cycle disorders—such as ornithine transcarbamylase, carbamoyl phosphate synthetase, and argininosuccinate synthetase deficiencies—typically serving as adjunctive therapy alongside dietary protein restriction to prevent hyperammonemic crises and permanent neurological damage
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.